Yankees rally with 2 outs in 9th inning and beat Braves 3-2 in 10 after long rain delay

NEW YORK (AP) — Ben Rice ripped a tying single off the right-field fence with two outs in the ninth inning and Ryan McMahon hit a game-winning sacrifice fly in the 10th as the New York Yankees rallied past the Atlanta Braves 3-2 on Friday night in a rain-delayed game that ended after midnight.

New York improved to 2-8 in extra-inning games, halting an eight-game winning streak overall for the NL East leaders.

Yankees left-hander Max Fried pitched 6 1/3 scoreless innings in his first outing against his former team, but Tyler Mahle matched him with six shutout innings in his Atlanta debut.

Austin Riley homered in the eighth and Matt Olson went deep in the ninth to give the Braves a 2-0 lead. With the Yankees down to their final out, slumping Austin Wells doubled home a run off All-Star closer Raisel Iglesias.

Amed Rosario walked before Rice singled on a 1-0 changeup.

Heliot Ramos was hit by a pitch to load the bases before Dylan Dodd entered and retired Luis García Jr. on a groundout to send the game to extra innings.

New York's rally began when rookie George Lombard Jr. reached on an infield single with one out and advanced to third on Iglesias' throwing error.

David Bednar (5-3) pitched a scoreless 10th, helped by Lombard's off-balance throw from shortstop on Sean Murphy’s grounder and García's over-the-shoulder catch at first base on Ronald Acuña Jr.'s popup to end the inning.

With one out in the bottom half, rookie Spencer Jones was intentionally walked and Lombard worked a walk from Tyler Kinley (6-5) that loaded the bases. García, the automatic runner, scored easily on McMahon's sac fly to deep right field on a full-count pitch as the Yankees improved to 5-42 when trailing through eight innings.

The start was delayed by heavy rain and thunderstorms for 1 hour, 55 minutes.

It was the eighth time in 10 games a Yankees starter permitted no more than one run.

Fried spent his first eight major league seasons with the Braves before leaving as a free agent to sign a $218 million, eight-year contract with New York in December 2024.

In a marquee matchup of Cy Young Award winners, Atlanta LHP Chris Sale (12-6, 2.08 ERA) pitches Saturday for the first time since July 29 when he faces New York RHP Gerrit Cole (5-5, 3.42) on Old Timers' Day at Yankee Stadium.

AP MLB: https://apnews.com/hub/mlb

Atlanta Braves' Matt Olson leaves the field after a baseball game against the New York Yankees Saturday, Aug. 8, 2026, in New York. (AP Photo/Frank Franklin II)

New York Yankees' Austin Wells hits an RBI double during the ninth inning of a baseball game against the Atlanta Braves Friday, Aug. 7, 2026, in New York. (AP Photo/Frank Franklin II)

New York Yankees' Ben Rice hits an RBI single during the ninth inning of a baseball game against the Atlanta Braves Friday, Aug. 7, 2026, in New York. (AP Photo/Frank Franklin II)

New York Yankees' Ryan McMahon, right, celebrates with teammates after a baseball game against the Atlanta Braves Saturday, Aug. 8, 2026, in New York. (AP Photo/Frank Franklin II)

New York Yankees' Ryan McMahon, center, celebrates with Heliot Ramos, right, Ben Rice, second from left, and Luis García Jr. after a baseball game against the Atlanta Braves Saturday, Aug. 8, 2026, in New York. (AP Photo/Frank Franklin II)

RAVENSBURG, Germany--(BUSINESS WIRE)--Sep 28, 2026--

Vetter, a leading Contract Development and Manufacturing Organization (CDMO), continues to expand its commercial fill-and-finish network to further strengthen its global manufacturing operations and support the evolving needs of pharma and biotech customers. The company’s long-term investment program includes the addition of ten more commercial filling lines.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928446750/en/

Seven of the ten planned manufacturing lines are being implemented across Vetter’s existing sites. This phased rollout will make additional manufacturing resources available over the coming years. The first new line, designed to fill pre-sterilized syringes, recently became operational, and a second line is expected to follow by the end of 2026. Another five lines for aseptic production are planned through 2028. Looking ahead, the final three lines are planned for Vetter’s new commercial site in Saarlouis, Germany, which is expected to become operational by 2031.

“Pharma and biotech companies seek partners with a proven track record, operational expertise, and the capabilities to support their current and future drug products,” states Managing Director Henryk Badack. “This demand is reflected in our strategy for sustainable growth. Through our ongoing investments, we are expanding our global manufacturing resources and strengthening our ability to support customers throughout the lifecycle of their products in international markets.”

Continued investment in Vetter’s broader operational infrastructure accompanies the expansion of its manufacturing capacity. Current initiatives include expanding compounding, pharmaceutical storage, and visual inspection capabilities, as well as implementing advanced cleanroom technology and increased automation and digitalization.

“Our phased approach enables us to make additional capacity available while systematically expanding our global production network,” explains Managing Director Carsten Press. “These investments provide customers with scalable operations, well-managed supply chains, and high-quality aseptic manufacturing to support their long-term growth.”

Vetter will be exhibiting at CPHI Milan from October 6 to 8, 2026, at booth 6A52, where company representatives will engage with customers and industry stakeholders to discuss current and future project requirements.

Find the Vetter press kit and more background information here.

About Vetter

Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the independent pharmaceutical service provider is also present in the Asia-Pacific markets of Japan, China, South Korea, and Singapore with sales locations. Around the world renowned pharma and biotech companies benefit from decades of experience, high quality, modern technologies, reliability, and commitment of its 7,400 employees. In close collaboration with its customers, the Vetter team helps enable the supply to patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative approaches, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. Vetter takes responsibility for sustainable practices and operates as a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received platinum status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership Award and the recognition of Best Managed Company emphasize Vetter’s commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.

© Vetter Pharma International GmbH: The latest filling line at Vetter’s commercial facility in Langenargen, Germany